BRAF G469V

CI-VAR-00001754Explore in graph →NP_004324.2:p.Gly469ValNM_004333.4:c.1406G>TClinVar 44803 CIViC 841 rs121913355

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
BRAF G469V	Dabrafenib + TrametinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID9513 Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469V increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC) PMID 28947956 · Noeparast et al., 2017 · Open in CIViC	civic
BRAF G469V	Sorafenib	Predictive	C	Supports Sensitivity Response	2	submitted	EID1939 Case report of a patient with HCC and NSCLC (only NSCLC harboring the BRAF G469V mutation). Sorafenib at standard dosage led to a partial response in the primary lesion of the lung, complete response … (full text at CIViC) PMID 27388325 · Casadei Gardini et al., 2016 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
44803	Pathogenic	criteria provided, single submitter	1	Non-small cell lung carcinoma; Low grade glioma	somatic	2	Dec 30, 2011	clinvar